Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal

• Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker-payload)
• Emergence Therapeutics secures rights to develop multiple ADCs against undisclosed targets to strengthen its ADC pipeline
• Emergence Therapeutics becomes the tenth company to license the Synaffix ADC technology platform in a deal with a total potential value of up to $360 million, plus royalties on commercial sales

Synaffix B.V. (Synaffix) and Emergence Therapeutics AG (“Emergence”) (“the Companies”) today announce that the Companies have entered into a licensing agreement of up to $360 million, providing Emergence access on a target-specific basis to Synaffix’s proprietary antibody drug conjugate (ADC) technologies comprising GlycoConnect™, HydraSpace™ and SYNtecan E™ linker-payload.

Under the terms of the agreement, Synaffix will be eligible to receive up to $360 million in upfront and milestone payments plus royalties on commercial sales. The first program will commence at signature, with the option to expand the collaboration to additional targets. The agreement is the result of positive proof of concept data following a successful initial discovery research collaboration between the companies. 

Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.